Conference Call and Webcast
Telik will conduct its quarterly conference call today at 4:30 p.m. Eastern time (1:30 pm. Pacific time). The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-553-5260 or 612-332-0720. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 956079. The archive will be available from approximately 6:30 p.m. Eastern time on August 11 through August 25, 2008.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.
This press release contains "forward-looking" statements, including
statements regarding Telik's future development of TELINTRA and TELCYTA.
These forward-looking statements are based upon Telik's current
expectations. There are important factors that could cause Telik's results
to differ materially from those indicated by these forward-looking
statements, including, among others, if clinical trials of TELINTRA or
TELCYTA are delayed or unsuccessful, Telik's business would suffer, if
Telik's competitors develop and market products that are more effective
than its product cand
|SOURCE Telik, Inc.|
Copyright©2008 PR Newswire.
All rights reserved